PEDIATRICS Vol. 99 No. 6 June 1997,
p. e11
Copyright ©1997 by the American Academy of Pediatrics
ELECTRONIC ARTICLE:
Lipoprotein (a): Its Role in Childhood Thromboembolism
Ulrike Nowak-Göttl,
Ottfried Debus,
Martina Findeisen,
Reiner Kassenböhmer,
Hans Georg Koch,
Harmut Pollmann,
Christiane Postler,
Peter Weber, and
Heinrich Vielhaber
From the Department of Paediatrics, University Hospital,
Münster, Germany.
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
ACKNOWLEDGMENTS
ABBREVIATIONS
REFERENCES
ABSTRACT
Purpose. Elevated lipoprotein (a)
[LP (a)] concentrations are independent risk factors of coronary
heart disease or stroke in young adults. To clarify its role in
childhood thromboembolism, Lp (a) was measured in 72 children with
thromboembolism.
Methods. In addition to Lp (a), defects of the protein C
anticoagulant system, antithrombin, and antiphospholipid antibodies were investigated in children with arterial (n = 36) or venous (n = 36) thrombosis.
Results. Enhanced Lp (a) >50 mg/dL was diagnosed in 8 out
of 36 children with arterial and 5 out of 36 patients with venous thrombosis. Of the 72 children, 25 showed the factor V Leiden mutation,
10 showed protein C deficiency, 2 showed antithrombin deficiency, and 4 showed primary antiphospholipid syndrome. Three children with increased
Lp (a) were heterozygous for the factor V Leiden mutation, and 1 girl
showed additional protein C deficiency.
Conclusions. Data of this study indicate that increased
concentrations of Lp (a) play an important role in childhood
thrombosis. childhood thrombosis, lipoprotein (a),
factor V Leiden, protein C.
INTRODUCTION
Lipoprotein (a) [Lp (a)] is a cholesterol-rich plasma
lipoprotein with a lipid composition similar to that of low-density lipoproteins (LDL). The protein composition is different from that of
LDL, consisting of two major proteins, apolipoprotein (apo) B and apo
(a).1,2 Lp (a) levels vary from person to person but
are genetically determined as a dominant trait, minimally affected by
race, age, and sex.3,4 Numerous groups agree in their
findings that individuals with increased concentrations of Lp (a) have
a higher risk of premature coronary heart disease,5 unrelated to the remaining lipoproteins. In addition, the risk of
stroke3,8 as well as for restenosis after coronary
artery bypass surgery13,14 correlates highly with increased
Lp (a) concentrations. Little is known, however, about the
relation between increased Lp (a) concentrations and childhood
thrombosis at various sites. We used a commercially available
enzyme-linked immunosorbent assay to measure Lp (a) in a population of
children with arterial or venous thrombosis.
METHODS
Seventy-two infants and children aged from birth to 18 years consecutively recruited between 1992 and 1996 and primarily
treated for arterial (n = 36) or venous (n = 36) thrombosis
were enrolled in this study. In the majority of cases arterial
thrombosis occurred in the central nervous system. Sixteen of 36 infants developed embolic stroke or multiple thrombosis in the neonatal
period (attributable to the uncertainty in differentiating between
embolic and local stroke in the majority of cases investigated, all
children with initial symptoms of stroke were categorized in the
arterial group). In addition, 11 children >1 year of age suffered an
ischemic embolic, local, or lacunar stroke. Left intracardial thrombus
formation was diagnosed in 4 of 36 patients, the femoral artery was
occluded in two children and aortic thrombosis was found in two
infants. Venous thromboses were found in the femoral vein (n = 10), renal veins (n = 8), superior caval vein (n = 6),
central nervous system (n = 7), and portal vein (n = 5),
respectively. In the majority of cases, underlying diseases triggering
the thromboembolic event were diagnosed. As in previous reports,
asphyxia, systemic infections, dehydration, congenital heart
disease, and central lines were commonly associated with the vascular
occlusion reported.15
Fasting venous blood samples for coagulation studies were obtained in
the acute phase of the vascular accident and at least 6 months after
the thrombotic episode when the children were free of anticoagulant
medication. In infants and children with suspected inherited
thrombophilia the final diagnosis was made when DNA-based assays
confirmed the diagnosis (Arg506 to Gln mutation of the factor V gene) or when repeatedly measured plasma concentrations were
outside the age-appropriate reference range and family screening confirmed the suspected inherited coagulation defect.20
Although the mean ± 2 standard deviation of the plasma values in
the control children was 25 mg/dL, we chose the markedly elevated
cut-off level of Lp (a) >50 mg/dL (2 × 25 mg/dL) according to
Margaglione et al12 in the present study. In addition,
bearing in mind the importance of Lp (a) as a risk factor of familial
thrombophilia, family data are included in this report.
Blood samples were drawn from a peripheral vein into premarked 3-mL
plastic tubes (citrate 3.8%/blood 1:10; Saarstedt, Nümbrecht, Germany), immediately placed on iced water and centrifuged at 4°C at
3000 g for 20 minutes. Platelet-poor plasma was snap-frozen and
stored in plastic tubes at
70°C. Lp (a) concentrations were measured with the enzyme-linked immunosorbent assay technique (COALIZA
Lp (a): Chromogenix, Mölndal, Sweden). The detection limit was .5 mg/dL and Lp (a) was quantified between 1 and 100 mg/dL. In addition,
the factor V Leiden mutation (DNA prepared from
ethylenediamine-tetraacetic acid blood), factor V, protein C, protein
S, antithrombin, and antiphospholipid antibodies (immunoglobulin M/immunoglobulin G) were measured as described earlier.23
Calculations of median and ranges and nonparametric statistics
(Wilcoxon-Mann-Whitney U test) were performed with the Apple computer Stat view program.
RESULTS
Table 1 shows the overall distribution of genetic risk
factors for familial thrombophilia in children with arterial and
venous thrombosis. Eight of 36 (22%) patients with arterial vascular insults and 5 of 36 (14%) with venous thrombosis showed Lp (a) concentrations >50 mg/dL. In addition, 244 age- and sex-matched healthy controls showed significantly lower (P < .001) median (range) Lp (a) plasma values of 7 mg/dL (0 to 39)
compared with 15 mg/dL (0 to 165) in children with venous thrombosis,
and 15 mg/dL (0 to 145) in patients with arterial vascular insults,
respectively. However, median (range) Lp (a) concentrations in infants
and children with venous vascular occlusion were no different from Lp
(a) values in the arterial group. With special regard to the markedly
elevated cut-off level of >50 mg/dL chosen in this study, single
patient values are given in Table 2.12 However,
if we had chosen mean ± 2 SD Lp (a) values of the control
children, the vascular accident would also have been classified as Lp
(a)-related in 5 of the remaining 28 patients (arterial) and 2 of 31 in
the venous group.
|
Table 1.
Incidence of Genetic Risk Factors for Thrombophilia in Children With
Arterial or Venous Thromboembolism
[View Table]
|
|
Table 2.
Lp (a) Concentration, Thrombus Location, and Affected Family Members in
Children With Familially Increased Lp(a) and Thromboembolism
[View Table]
|
In addition, 25 of the 72 children showed the factor V Leiden
mutation, 10 protein C type I deficiency, and two antithrombin type I
deficiency. Four of the 72 children showed primary antiphospholipid syndrome. Three children with increased Lp (a) were heterozygous for
the factor V Leiden mutation, and one girl showed an additional protein
C deficiency (Table 2). Eleven of 13 patients with thrombosis and Lp
(a) >50 mg/dL had a positive family history of early myocardial infarction (n = 6), stroke (n = 4), or venous thrombosis
(n = 1) (Table 2).
No factor V or protein S deficiency was diagnosed in the population
studied.
DISCUSSION
Data of this study indicate that 58% of children with arterial
thrombosis and 80% of children with venous thrombosis had genetic risk
factors of familial thrombophilia. Besides inherited defects in the
protein C anticoagulant pathway, recently reported in a smaller group
of children,23 increased concentrations of Lp (a) play
an important role in the etiology of childhood thromboembolism.
Lp (a) was first described in human plasma by Berg as a genetic variant
of
-lipoprotein.24 Lp (a) levels are reported to be
regulated by a gene located on the long arm of chromosome 6 close to
the gene for plasminogen. Complementary DNA sequencing of human apo (a)
showed it to be closely homologous with plasminogen.25 This
fact is assumed to provide a direct link between thrombogenesis and
atherosclerosis.26,27 In addition, it has been speculated that high plasma Lp (a) levels might also be a marker of the early presence of atherosclerotic lesions at extracoronary
sites.28
Besides increased Lp (a) levels in children with thrombosis, 11 of 13 patients with thrombosis and Lp (a) >50 mg/dL in this study had a
positive family history of early myocardial infarction, stroke, or
venous thrombosis. These findings confirm literature data claiming that
increased levels of Lp (a) in infancy and childhood were significantly
associated with thromboembolism in the patients' parents or
grandparents.29 However, further studies are needed to
evaluate whether general neonatal Lp (a) screening could detect families at risk of vascular accidents or could prevent the early onset
of thromboembolism in the families affected.32
FOOTNOTES
Received for publication Sep 17, 1996; accepted Feb 7, 1997.
Reprint requests to (U.N.-G.) Westfälische
Wilhelms-Universität, Paediatric Haematology and Oncology,
Albert-Schweitzer-Str. 33, D-48149 Münster, Germany.
ACKNOWLEDGMENTS
The authors thank Susan Griesbach for editing this manuscript.
Participating investigators, besides the authors, were S. Eckhoff-Donovan (Düsseldorf), T. Frank (Münster), and
N. Jorch (Bielefeld).
ABBREVIATIONS
Lp (a), lipoprotein (a).
LDL, low-density
lipoprotein.
apo, apolipoprotein.
REFERENCES
-
Armstrong VW,
Walli AK,
Seidel D
Isolation, characterization and
uptake in human fibroblasts of an apo (a)-free lipoprotein obtained on
reduction of lipoprotein (a).
J Lipid Res
1985;
26:1314-1323 [Medline][Abstract]
-
Seman LJ,
Breckenridge WC
Isolation and partial characterization of
apolipoprotein (a) from human lipoprotein (a).
Biochem Cell
Biol
1986;
64:999-1009 [Medline][Medline]
-
Zenker G,
Költringer P,
Bone G,
Niederkorn K,
Pfeiffer K,
Jürgens G
Lipoprotein (a) as a strong indicator for
cerebrovascular disease.
Stroke
1986;
17:942-945 [Medline][Abstract/Free Full Text]
-
Albers JJ,
Hazzard WR
Immunochemical quantification of human plasma Lp
(a) lipoprotein.
Lipids
1974;
9:15-26 [Medline][CrossRef][Medline]
-
Berg K,
Dahlen G,
Frick MH
Lp (a) lipoprotein and pre-beta 1 lipoprotein in patients with coronary heart disease.
Clin
Genet
1974;
6:230-235 [Medline][Medline]
-
Seed M,
Hoppichler F,
Reaveley D,
Relation of serum lipoprotein
(a) concentration and apolipoprotein (a) phenotype to coronary heart
disease in patients with familial hypercholesterolemia.
N
Engl J Med
1990;
322:1494-1499 [Medline][Abstract]
-
Sandkamp M,
Funke H,
Schulte H,
Köhler E,
Assmann G
Lipoprotein
(a) is an independent risk factor for myocardial infarction at a young
age.
Clin Chem
1990;
36:20-23 [Medline][Abstract/Free Full Text]
-
Murai A,
Miyahara T,
Fujimoto N,
Matsuda M,
Kameyama M
Lp (a)
lipoprotein as a risk factor for coronary heart disease and cerebral
infarction.
Atherosclerosis
1986;
59:199-204 [Medline][CrossRef][Medline]
-
Nagayama M,
Shinohara Y,
Nagayama T
Lipoprotein (a) and ischemic
cerebrovascular disease in young adults.
Stroke
1994;
25:74-78 [Medline][Abstract]
-
Jürgens G,
Költringer P
Cerebrovascular disease and Lp
(a): its role in atherosclerotic plaque formation and vessel wall
elasticity of the carotid arteries.
Chem Phys Lipids
1994;
68:429-434[CrossRef]
-
Woo J,
Lau E,
Lamm CWK,
Hypertension, lipoprotein (a), and
apolipoprotein A-I as risk factors for stroke in the Chinese.
Stroke
1991;
22:203-208 [Medline][Abstract/Free Full Text]
-
Margaglione M,
Di Minno G,
Grandone E,
Plasma lipoprotein (a)
levels in subjects attending a metabolic ward.
Arterioscler
Thromb Vasc Biol
1996;
16:120-128 [Medline][Abstract/Free Full Text]
-
Hoff HF,
Beck GJ,
Skibinski CI,
Serum Lp (a) levels as a
predictor of vein graft stenosis after coronary artery bypass surgery
in patients.
Circulation
1988;
77:1238-1244 [Medline][Abstract/Free Full Text]
-
Rath M,
Niendorf A,
Reblin T,
Dietel M,
Krebber HJ,
Beisiegel U
Detection and quantification of lipoprotein (a) in the arterial wall of
107 coronary by-pass patients.
Atherosclerosis
1989;
9:579-592
-
Andrew M
Developmental hemostasis: relevance to thromboembolic
complications in pediatric patients.
Thromb Haemost
1995;
74:415-425 [Medline][Medline]
-
Kohlhase B,
Vielhaber H,
Kehl HG,
Kececioglu D,
Koch HG,
Nowak-Göttl U
Thromboembolism and resistance to activated
protein C in children with underlying cardiac disease.
J
Pediatr
1996;
129:677-679 [Medline][CrossRef][Medline]
-
Nowak-Göttl U, Kries von R, Göbel U. Neonatal symptomatic
thromboembolism in Germany: report of a prospective registry.
Arch Dis Child. 1997. In press
-
Nowak-Göttl U, Dübbers A, Kececioglu D, et al. Factor V
Leiden, protein C and lipoprotein (a) in catheter-related thrombosis in
childhood
a prospective study. J Pediatr. 1997. In
press -
Schmidt B,
Andrew M
Neonatal thrombosis: report of a prospective
Canadian and international registry.
Pediatrics
1995;
96:936-934
-
Andrew M,
Paes B,
Milner R,
Johnston M
Development of the hemostatic
system in the neonate and young infant.
Am J Pediatr Hematol
Oncol
1990;
12:95-104 [Medline][Medline]
-
Andrew M,
Vegh P,
Johnston M,
Bowker J,
Ofosu F,
Mitchell L
Maturation
of the hemostatic system during childhood.
Blood
1992;
80:1998-2005 [Medline][Abstract/Free Full Text]
-
Nowak-Göttl U,
Funk M,
Mosch G,
Wegerich B,
Kornhuber B,
Breddin HK
Univariate tolerance regions for fibrinogen, antithrombin III,
protein C, protein S, plasminogen and a2-antiplasmin in children using
the new automated coagulation laboratory (ACL) method.
Klin
Padiatr
1994;
206:437-439 [Medline][Medline]
-
Nowak-Göttl U,
Koch HG,
Aschka I,
Resistance to activated
protein C (APCR) in children with venous or arterial thromboembolism.
Br J Haematol
1996;
92:992-998 [Medline][CrossRef][Medline]
-
Berg K
A new serum type system in man
the Lp-system.
Acta
Pathol Microbiol Scand
1963;
59:369-383[Medline] -
McLean JW,
Tomlinson JE,
Kuang WJ,
Eaton DL,
Chen EY,
Fless GM,
Scanu AM,
Lawn RM
cDNA sequence of human apolipoprotein (a) is homologous to
plasminogen.
Nature
1987;
300:132-137
-
Miles LA,
Fless GM,
Levin EG,
Scanu AM,
Plow EF
A potential basis for
the thrombotic risk associated with lipoprotein (a).
Nature
1989;
339:301-303 [Medline][CrossRef][Medline]
-
Utermann G
The mysteries of lipoprotein (a).
Science
1989;
246:904-910 [Medline][Abstract/Free Full Text]
-
Cambillau M,
Simon A,
Amar J,
Serum Lp (a) as a discriminant
marker of early atherosclerotic plaques at three extracoronary sites in
hypercholestrolemic men.
Arterioscl Thromb
1992;
12:1346-1352 [Medline][Abstract/Free Full Text]
-
Wang XL,
Wilcken DEL,
Dudman NPB
Early expression of the
apolipoprotein (a) gene: relationship between infants` and their
parents` serum apolipoprotein (a) levels.
Pediatrics
1992;
89:401-406 [Medline][Abstract/Free Full Text]
-
Gomez Gerique JA, Porres A, Lopez Martinez D, Alvarez Sala LA, Blazques
E, Montoya MT, De Oya M
Levels of lipoprotein (a) and plasma lipids in
Spanish children aged from 4 to 18 years.
Acta Paediatr
1996;
85:38-42[Medline]
-
Wilcken DEL,
Wang XL,
Greenwood J,
Lynch J
Lipoprotein (a) and
apoproteins B and A-1 in children and coronary vascular events in their
grandparents.
J Pediatr
1993;
123:519-526[CrossRef][Medline]
-
Wang XL,
Wicken SEL,
Dudman NPB
Neonatal apo A-I, apo B and apo (a)
levels in dried blood spots in an Australian population.
Pediatr
Res
1990;
28:496-501 [Medline]
[Medline]